MetaCap

Alpha Teknova (TKNO) vs Trinity Biotech (TRIB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Alpha Teknova is the larger company by market cap ($480.0 million vs $5.1 million), about 94.6 times the size, while Trinity Biotech is growing revenue faster (+8.3% vs +7.4%). Alpha Teknova converts more of its revenue into profit, with a net margin of -42.6% versus -51.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

TKNO-12.40%TRIB-7.56%
+24%-6%-36%
Oct 7, 20261 yearNov 20, 2026
TKNO-13.69%TRIB-8.97%
+19%-5%-30%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

TKNO versus TRIB key metrics
MetricTKNOTRIB
Share price$7.63$6.24
Market cap$479.95M$5.07M
1-day change-2.30%+13.76%
YTD return+100.79%—
1-year return+77.44%—
5-year return-63.63%—
EPS (TTM)$-0.30$-60.00
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$40.52M$61.55M
Revenue growth (YoY)+7.35%+8.31%
Net income (latest FY)$-17.26M$-31.79M
Gross margin33.17%34.83%
Operating margin-41.90%-34.38%
Net margin-42.59%-51.64%
52-week high$9.48$52.50
52-week low$1.91$4.54
Distance from 52-week high-19.51%-88.11%
Analyst consensusnone—
Avg. price target upside+28.83%—
Average volume437.31K13.54K
Shares outstanding62.90M813.13K
Employees158287
SectorHealth CareHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic SubstancesBiotechnology: In Vitro & In Vivo Diagnostic Substances

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Alpha Teknova is about 94.6 times larger than Trinity Biotech by market value ($479.95M vs $5.07M).
  • Alpha Teknova is more profitable, keeping -42.6 cents of every revenue dollar as net income versus -51.6 cents for Trinity Biotech.

About Alpha Teknova

TKNO stock →

Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 158 employees

About Trinity Biotech

TRIB stock →

Trinity Biotech plc, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases, such as syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 287 employees

TKNO vs TRIB FAQ

Which is bigger, Alpha Teknova or Trinity Biotech?

Alpha Teknova (TKNO) is larger, with a market capitalization of $479.95M compared with $5.07M for Trinity Biotech (TRIB).

Are Alpha Teknova and Trinity Biotech in the same industry?

Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.

More comparisons